Literature DB >> 19657649

Multidetector CT predictors of incomplete resection in primary cytoreduction of patients with advanced ovarian cancer.

Dae Chul Jung1, Sokbom Kang, Min Ju Kim, Sang Yoon Park, Hyun Beom Kim.   

Abstract

This study was designed to develop a preoperative predictor model using multidetector CT (MDCT) imaging findings for the prediction of surgical outcome in patients with advanced epithelial ovarian cancer (EOC). Seventy-seven patients with advanced EOC who had preoperative MDCT and who had undergone primary cytoreductive surgery between January 1999 and June 2008 were enrolled in the study. All MDCT examinations were analysed retrospectively, assessing nine imaging features without knowledge of the operative findings. The complete debulking rate and optimal debulking rate were 42.5% and 93.2%, respectively. Based on the use of univariate and multivariate analysis, one imaging feature that showed the presence of upper abdominal ascites was significantly associated with incomplete tumour resection (P = 0.019 on univariate analysis, P = 0.04 on multivariate analysis). The combination of the MDCT findings that showed the presence of upper abdominal ascites and diffuse subdiaphragmatic peritoneal nodularity was associated with an incomplete resection of a tumour (P = 0.04; specificity 80.0%; positive predictive value 76.9%). It is important that emphasis on the upper abdominal sites of the tumour is helpful when reporting preoperative MDCT results.

Entities:  

Mesh:

Year:  2009        PMID: 19657649     DOI: 10.1007/s00330-009-1533-0

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  44 in total

1.  A multidisciplinary approach to ovarian cancer at diagnosis.

Authors:  J A Spencer
Journal:  Br J Radiol       Date:  2005       Impact factor: 3.039

Review 2.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

Review 3.  Diagnosis and management of epithelial ovarian cancer.

Authors:  Snehal Bhoola; William J Hoskins
Journal:  Obstet Gynecol       Date:  2006-06       Impact factor: 7.661

4.  Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer.

Authors:  Elise N Everett; Amy E French; Rebecca L Stone; Lisa M Pastore; Amir A Jazaeri; Willie A Andersen; Peyton T Taylor
Journal:  Am J Obstet Gynecol       Date:  2006-08       Impact factor: 8.661

5.  Survival of patients following secondary cytoreductive surgery in ovarian cancer.

Authors:  J S Berek; N F Hacker; L D Lagasse; R K Nieberg; R M Elashoff
Journal:  Obstet Gynecol       Date:  1983-02       Impact factor: 7.661

6.  Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer.

Authors:  Allison E Axtell; Margaret H Lee; Robert E Bristow; Sean C Dowdy; William A Cliby; Steven Raman; John P Weaver; Mojan Gabbay; Michael Ngo; Scott Lentz; Ilana Cass; Andrew J Li; Beth Y Karlan; Christine H Holschneider
Journal:  J Clin Oncol       Date:  2007-02-01       Impact factor: 44.544

Review 7.  The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer.

Authors:  J Huober; A Meyer; U Wagner; D Wallwiener
Journal:  J Cancer Res Clin Oncol       Date:  2002-01-29       Impact factor: 4.553

8.  Predictors of suboptimal surgical cytoreduction in women with advanced epithelial ovarian cancer treated with initial chemotherapy.

Authors:  A E Bland; E N Everett; L M Pastore; W A Andersen; P T Taylor
Journal:  Int J Gynecol Cancer       Date:  2007-11-06       Impact factor: 3.437

9.  The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma.

Authors:  Sean C Dowdy; Sally A Mullany; Kathy R Brandt; Bonnie J Huppert; William A Cliby
Journal:  Cancer       Date:  2004-07-15       Impact factor: 6.860

10.  Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma.

Authors:  B E Nelson; A T Rosenfield; P E Schwartz
Journal:  J Clin Oncol       Date:  1993-01       Impact factor: 44.544

View more
  4 in total

1.  High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes.

Authors:  Stephanie Nougaret; Yulia Lakhman; Mithat Gönen; Debra A Goldman; Maura Miccò; Melvin D'Anastasi; Sarah A Johnson; Krishna Juluru; Angela G Arnold; Ramon E Sosa; Robert A Soslow; Hebert Alberto Vargas; Hedvig Hricak; Noah D Kauff; Evis Sala
Journal:  Radiology       Date:  2017-06-16       Impact factor: 11.105

2.  A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.

Authors:  Rudy S Suidan; Pedro T Ramirez; Debra M Sarasohn; Jerrold B Teitcher; Revathy B Iyer; Qin Zhou; Alexia Iasonos; John Denesopolis; Oliver Zivanovic; Kara C Long Roche; Yukio Sonoda; Robert L Coleman; Nadeem R Abu-Rustum; Hedvig Hricak; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2017-02-14       Impact factor: 5.482

3.  The use of CT findings to predict extent of tumor at primary surgery for ovarian cancer.

Authors:  Gretchen Glaser; Michelle Torres; Bohyun Kim; Giovanni Aletti; Amy Weaver; Andrea Mariani; Lynn Hartmann; William Cliby
Journal:  Gynecol Oncol       Date:  2013-05-11       Impact factor: 5.482

4.  Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study.

Authors:  Marianne J Rutten; Katja N Gaarenstroom; Toon Van Gorp; Hannah S van Meurs; Henriette Jg Arts; Patrick M Bossuyt; Henk G Ter Brugge; Ralph Hm Hermans; Brent C Opmeer; Johanna Ma Pijnenborg; Henk Wr Schreuder; Eltjo Mj Schutter; Anje M Spijkerboer; Celesta Wm Wensveen; Petra Zusterzeel; Ben Willem J Mol; Gemma G Kenter; Marrije R Buist
Journal:  BMC Cancer       Date:  2012-01-20       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.